Nine babies are stillborn every day in the UK. We’re funding vital studies to understand the conditions that can cause stillbirth and late miscarriage, and identify how they can be prevented. Following landmark research on the microbiome, funded by Genesis in 2015 and 2016, we are now aiming to fund development of a targeted antibiotic and probiotic treatment that can change the profile of bacteria in the reproductive tract and reduce the risk of miscarriage, stillbirth, ectopic pregnancy and preterm birth.
